Scinai Immunotherapeutics (SCNI) Cash from Operations (2018 - 2024)

Scinai Immunotherapeutics has disclosed Cash from Operations across 7 years of filings, most recently posting 1076000.0 for Q4 2024.

• Cash from Operations for Q4 2024 came in at 1076000.0, up 12.16% year-over-year; the trailing twelve-month figure through Dec 2024 was 6335000.0 (up 32.48% YoY), and the FY2025 annual result was 6031000.0, up 4.8% from the prior year.
• Cash from Operations came in at 1076000.0 for Q4 2024 at Scinai Immunotherapeutics, up from 2038000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 593000.0 in Q4 2022 to a low of 15907000.0 in Q4 2020.
• The 5-year median for Cash from Operations is 2038000.0 (2024), against an average of 4113684.21.
• Across the five-year window, Cash from Operations surged 88.29% in 2021 and plunged 176.83% in 2023, its largest moves.
• Scinai Immunotherapeutics' Cash from Operations stood at 15907000.0 in 2020, then soared by 88.29% to 1863000.0 in 2021, then surged by 68.17% to 593000.0 in 2022, then plunged by 106.58% to 1225000.0 in 2023, then increased by 12.16% to 1076000.0 in 2024.
• The last three Cash from Operations figures came in at 1076000.0 (Q4 2024), 2038000.0 (Q3 2024), and 1758000.0 (Q2 2024), per Business Quant data.